Biosion
Dr. Zhu brings to Biosion over 13 years of regulatory experience as a medical officer/clinical reviewer at US FDA. In this capacity Dr. Zhu participated in the review of both biologics and small molecule products with a wide range of indications at different stages of clinical development, contributing as a primary reviewer to the market approval of BYLVAY™, TRALEMENT™, LUXTURNA™, DUCORD™, and LAVIV™. In addition, Dr. Zhu has over 20 years of clinical experience as an internal medicine physician, working and teaching at medical centers such as the Greater Baltimore Medical Center and Johns Hopkins School of Medicine.
This person is not in any offices
Biosion
Biosion is a leading “In Global For Global” clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide.